Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients

We aimed to explore the role of drugs re-challenge at the disease progression after a chemotherapy-free interval for pancreatic adenocarcinoma (PDAC) patients. We retrospectively analyzed the outcome of re-treatments at the progression in two cohorts of advanced PDAC patients who had disease control (DC) and a treatment holiday ≥ 3 months after upfront chemotherapy. Between 2015 and 2019, 66 advanced PDAC patients (cohort A) had DC with...